Skip to main content

Table 4 Treatment differences between groups according to genotypes in LEP, NPY and PYY genes

From: Polymorphisms in LEP and NPY genes modify the response to soluble fibre Plantago ovata husk intake on cardiovascular risk biomarkers

Gene

SNP

Response

Baseline

Genotype

Treatment

N

Change at 8 weeks relative to baseline (% change from baseline)a

Treatment differences (% difference from placebo)b

p c

Mean

SD

LEP

rs7799039

CT

Placebo

6.566

0.801

GG

Placebo

Po-husk

26

−0.070 [−0.183; 0.043] (−1.066)

−0.286 [−0.392; −0.179] (−4.375)

−0.216 [−0.374; −0.058] (−3.309)

0.008

29

Po-husk

6.537

0.641

GA + AA

Placebo

Po-husk

49

−0.172 [−0.245; −0.099] (−2.619)

−0.132 [−0.207; −0.057] (−2.019)

0.040 [−0.065; 0.146] (0.600)

0.452

46

LEP

rs2167270

CT

Placebo

6.566

0.801

GG + GA

Placebo

Po-husk

67

−0.156 [−0.218; −0.094] (−2.376)

−0.159 [−0.221; −0.097] (−2.432)

−0.003 [−0.092; 0.085] (−0.056)

0.940

67

Po-husk

6.537

0.641

AA

Placebo

Po-husk

8

−0.053 [−0.325; 0.220] (−0.807)

−0.420 [−0.675; −0.164] (−6.425)

−0.367 [−0.759; 0.024] (−5.618)

0.063

9

NPY

rs16147

sBP

Placebo

126.930

14.474

AA

Placebo

Po-husk

20

0.896 [−3.772; 5.564] (0.706)

−7.140 [−11.080; −3.199] (−5.501)

−8.035 [−14.165; −1.905] (−6.207)

0.011

28

Po-husk

129.795

16.608

AG + GG

Placebo

Po-husk

60

−0.374 [−2.844; 2.096] (−0.295)

−3.746 [−6.599; −0.892] (−2.886)

−3.371 [−7.151; 0.409] (−2.591)

0.080

45

NPY

rs16147

hsCRP

Placebo

1.999

1.881

AA

Placebo

Po-husk

16

0.127 [−0.268; 0.525] (6.353)

−0.437 [−0.758; −0.117] (−18.517)

−0.564 [−1.079; −0.049] (−24.870)

0.033

24

Po-husk

2.360

1.963

AG + GG

Placebo

Po-husk

42

0.128 [−0.213; 0.469] (6.403)

0.205 [−0.160; 0.569] (8.686)

0.077 [−0.429; 0.582] (2.283)

0.764

39

PYY

rs162430

TG

Placebo

1.203

0.558

CC

Placebo

Po-husk

59

0.017 [−0.081; 0.116] (1.413)

0.022 [−0.080; 0.124] (1.720)

0.005 [−0.137; 0.146] (0.307)

0.946

57

Po-husk

1.279

0.635

CT + TT

Placebo

Po-husk

13

0.111 [−0.185; 0.407] (9.227)

−0.240 [−0.498; 0.018] (−18.764)

−0.351 [−0.743; 0.041] (−27.991)

0.077

16

  1. SNP single-nucleotide polymorphism, CT total cholesterol, sBP systolic blood pressure, hsCRP high sensitive C-reactive protein, TG triglycerides
  2. aEfficacy variables calculated as changes from baseline to week 8. Values are baseline-adjusted least-square means and 95 % confidence intervals
  3. bTreatment differences values are adjusted least-square means and 95 % confidence intervals
  4. cDifferences in means values were assessed by ANOVA adjusted by covariates